A preliminary study on stereotactic ablative brachytherapy for lung metastases from cervical cancer
LIU Ying1, ZHOU Yun1,2, XIE Xiaoxuan1, REN Hongrong1, LI Na1, HUI Hui1, JIANG Wei3
1. Xuzhou Central Hospital, Xuzhou 221000 China; 2. Xuzhou Clinical School of Xuzhou Medical University, Xuzhou 221000 China; 3. Fengxian People’s Hospital, Xuzhou 221700 China
[1] Ki EY, Lee KH, Park JS, et al. A clinicopathological review of pulmonary metastasis from uterine cervical cancer[J]. Cancer Res Treat, 2016, 48(1): 266-272. DOI: 10.4143/crt.2014.206 [2] 郑爱文, 陈雅卿, 方静, 等. 早期子宫颈癌术后肺转移的临床病理特征及危险因素分析[J]. 中华妇产科杂志,2015,50(3):204-209. DOI: 10.3760/cma.j.issn.0529-567x.2015.03.008 Zheng AW, Chen YQ, Fang J, et al. Clinicopathologic characteristics and risk factors for lung metastasis after radical hysterectomy in early-stage cervical cancer[J]. Chin J Obstet Gynecol, 2015, 50(3): 204-209. DOI: 10.3760/cma.j.issn.0529-567x.2015.03.008 [3] Shiromizu K, Kasamatsu T, Takahashi M, et al. A clinicopathological study of postoperative pulmonary metastasis of uterine cervical carcinomas[J]. J Obstet Gynaecol Res, 1999, 25(4): 245-249. DOI: 10.1111/j.1447-0756.1999.tb01156.x [4] Li HR, Wu XH, Cheng X. Advances in diagnosis and treatment of metastatic cervical cancer[J]. J Gynecol Oncol, 2016, 27(4): e43. DOI: 10.3802/jgo.2016.27.e43 [5] National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): cervical cancer[EB/OL]. 2022. http://www.nccn.org/guidelines/guidelines-detail?category=1&id=1426. [6] 刘亚洲, 袁成, 施林心, 等. 放射性粒子植入技术治疗恶性肿瘤进展[J]. 中国辐射卫生,2018,27(4):390-394. DOI: 10.13491/j.issn.1004-714X.2018.04.027 Liu YZ, Yuan C, Shi LX, et al. Progress of radioactive seed implantation in the treatment of malignant tumors[J]. Chin J Radiol Health, 2018, 27(4): 390-394. DOI: 10.13491/j.issn.1004-714X.2018.04.027 [7] Sharma DN, Rath GK, Thulkar S, et al. Computerized tomography-guided percutaneous high-dose-rate interstitial brachytherapy for malignant lung lesions[J]. Cancer Res Ther, 2011, 7(2): 174-179. DOI: 10.4103/0973-1482.82914 [8] Fowler JF. The Linear-quadratic formula and progress in fractionated radiotherapy[J]. Br J Radiol, 1989, 62(740): 679-694. DOI: 10.1259/0007-1285-62-740-679 [9] 鲁旭尉. 一种后装治疗辐射源的质量保证方法[J]. 中国辐射卫生,2017,26(4):472-473. DOI: 10.3969/j.issn.1004-714X.2017.04.033 Lu XW. A method on quality assurance of γ source of brachytherapy device[J]. Chin J Radiol Health, 2017, 26(4): 472-473. DOI: 10.3969/j.issn.1004-714X.2017.04.033 [10] Palma DA, Nguyen TK, Kwan K, et al. Short report: interim safety results for a phase II trial measuring the integration of stereotactic ablative radiotherapy (SABR) plus surgery for early stage non-small cell lung cancer (MISSILE-NSCLC)[J]. Radiat Oncol, 2017, 12(1): 30. DOI: 10.1186/s13014-017-0770-7 [11] 石翔翔, 庞皓文, 孙小杨, 等. 可手术周围型非小细胞肺癌192铱源大分割立体后装放射消融术新辅助治疗的效果评价[J]. 肿瘤防治研究,2019,46(2):164-168. DOI: 10.3971/j.issn.1000-8578.2019.18.1112 Shi XX, Pan HW, Sun XY, et al. Evaluation of 192Ir-based hypofractionated stereotactic ablative brachytherapy as a neoadjuvant treatment for operable peripheral non-small cell lung cancer[J]. Cancer Res Prev Treat, 2019, 46(2): 164-168. DOI: 10.3971/j.issn.1000-8578.2019.18.1112 [12] Li X, Zhang JW, Lin S, et al. Computed tomography-guided interstitial high-dose-rate brachytherapy in combination with regional positive lymph node intensity-modulated radiation therapy in locally advanced peripheral non-small cell lung cancer: a phase 1 clinical trial[J]. Int J Radiat Oncol Biol Phys, 2015, 92(5): 1027-1034. DOI: 10.1016/j.ijrobp.2015.04.019 [13] Patel RB, Baniel CC, Sriramaneni RN, et al. Combining brachytherapy and immunotherapy to achieve in situ tumor vaccination: a review of cooperative mechanisms and clinical opportunities[J]. Brachytherapy, 2019, 18(2): 240. DOI: 10.1016/j.brachy.2019.01.004 [14] Vanpouille-Box C, Alard A, Aryankalayil MJ, et al. DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity[J]. Nat Commun, 2017, 8(1): 15618. DOI: 10.1038/ncomms15618 [15] Yuan ZG, Fernandez D, Dhillon J, et al. Proof-of-principle phase I results of combining nivolumab with brachytherapy and external beam radiation therapy for grade group 5 prostate cancer: safety, feasibility, and exploratory analysis[J]. Prostate Cancer Prostatic Dis, 2021, 24(1): 140-149. DOI: 10.1038/s41391-020-0254-y [16] Sui AX, Song HL, Yu HM, et al. Clinical application of iodine-125 seed brachytherapy combined with Anti-PD-1 antibodies in the treatment of lung cancer[J]. Clin Ther, 2020, 42(8): 1612-1616. DOI: 10.1016/j.clinthera.2020.05.018 [17] Xia N, Pang HP, Gong J, et al. Robo1-specific CAR-NK immunotherapy enhances efficacy of 125I seed brachytherapy in an orthotopic mouse model of human pancreatic carcinoma[J]. Anticancer Res, 2019, 39(11): 5919-5925. DOI: 10.21873/anticanres.13796
